aromasil has been researched along with abiraterone acetate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Griffin, TW; Hayes, D; Johnston, S; Kheoh, T; Martin, J; Neven, P; O'Shaughnessy, J; Peng, W; Yu, MK | 1 |
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Gormley, M; Graas, MP; Griffin, T; Hayes, D; Ivanova, O; Johnston, SR; Kheoh, T; Li, W; Martin, J; Neven, P; O'Shaughnessy, J; Ricci, D; Schaffer, M; Stenina, M; Yu, M; Zbarskaya, I; Zelinsky, K | 1 |
2 trial(s) available for aromasil and abiraterone acetate
| Article | Year |
|---|---|
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Treatment Outcome | 2016 |
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Receptors, Androgen; Receptors, Estrogen; Steroid 17-alpha-Hydroxylase | 2016 |